Literature DB >> 9444442

Paget's disease of bone: indications for treatment and goals of therapy.

R D Tiegs1.   

Abstract

Paget's disease of bone is a common disorder of unknown etiology characterized by increased bone remodeling and abnormal bone architecture. The pathologic process is initiated by an increase in osteoclast-mediated bone resorption, accompanied by a compensatory increase in bone formation. The increased bone remodeling results in a disorganized mosaic of woven and lamellar bone. This bone is highly vascular and gradually becomes enlarged and structurally weakened. Paget's disease is generally diagnosed in patients older than 40 years of age, usually as an incidental finding. The disease may be monostotic or polyostotic. The pelvis, femur, spine, tibia, skull, and humerus are most commonly involved. Most patients with Paget's disease are asymptomatic. Pain is the most common presenting symptom. Complications of the disease include bowing deformity of the long bones, fracture, and a variety of nerve compression syndromes. Malignant degeneration of Paget's disease is a rare complication. As safer, more effective therapies have become available, the indications for treatment and goals of therapy have changed. The difficult issue that clinicians are currently facing is whether to treat patients with asymptomatic disease. The progressive nature of the disease, the severity of its complications, its potential negative impact on quality of life, and the availability of therapy capable of controlling its activity have led many experts in the field to recommend treatment of asymptomatic patients who have active disease at sites where complications are likely to develop. There are, however, no data to prove that complications can be prevented by decreasing the rate of bone remodeling in Paget's disease, nor any data to define who is at risk for complications. Until more information is available, the management of patients with Paget's disease will continue to be based on clinical observation and theoretical considerations. This review examines the present understanding of Paget's disease, the rationale for the proposed indications for treatment and the goals of therapy.

Entities:  

Mesh:

Year:  1997        PMID: 9444442     DOI: 10.1016/s0149-2918(97)80007-0

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  6 in total

1.  Monostotic Paget's disease of the tibia in Korea.

Authors:  Chan-Hee Lee; Sung-Hun Han; Bo-Young Yoon; Yun-Woo Lee
Journal:  Clin Rheumatol       Date:  2004-04-14       Impact factor: 2.980

2.  Active Paget's disease of bone with normal biomarkers of bone metabolism: a case report and review of the literature.

Authors:  Lamprini Gkouva; Maria Andrikoula; Vasilis Kontogeorgakos; Dionysios J Papachristou; Agathocles Tsatsoulis
Journal:  Clin Rheumatol       Date:  2010-10-01       Impact factor: 2.980

Review 3.  Asymptomatic Paget's bone disease in ethnic Thais: a series of four case reports and a review of the literature.

Authors:  Vorachai Sirikulchayanonta; Suphaneewan Jaovisidha; Thanya Subhadrabandhu; Rajata Rajatanavin
Journal:  J Bone Miner Metab       Date:  2011-11-16       Impact factor: 2.626

Review 4.  Principles of management of osteometabolic disorders affecting the aging spine.

Authors:  Alexander G Hadjipavlou; Paul G Katonis; Michael N Tzermiadianos; George M Tsoukas; George Sapkas
Journal:  Eur Spine J       Date:  2003-09-23       Impact factor: 3.134

5.  Patterns of pain in Paget's disease of bone and their outcomes on treatment with pamidronate.

Authors:  Sreekanth Vasireddy; Amruta Talwalkar; Hazel Miller; Rakesh Mehan; David R Swinson
Journal:  Clin Rheumatol       Date:  2003-10-17       Impact factor: 2.980

6.  The Use of Patient-Specific Induced Pluripotent Stem Cells (iPSCs) to Identify Osteoclast Defects in Rare Genetic Bone Disorders.

Authors:  I-Ping Chen
Journal:  J Clin Med       Date:  2014-12-17       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.